Changshan Biochemical Pharmaceutical (300255.SZ) stated on its investor interaction platform on June 5th that the company's low molecular weight heparin products are mainly sold domestically and the international export sales ratio is not high, but the company regards heparin export as an important direction for future development. The company's heparin products have been registered abroad in the past two years, and the registration work for the company's heparin products in the EU and the United States is also actively being pushed forward.
常山药业(300255.SZ)：低分子肝素制剂产品，目前主要是以国内销售为主，国际出口销量占比不高
Hebei Changshan Biochemical Pharmaceutical (300255.SZ): Low molecular weight heparin preparation products, mainly sold domestically, with a low proportion of international exports.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.